Compounds and compositions for treating polycystic ovary syndrome
A polycystic ovary and compound technology, which is applied in the field of compounds and compositions for the treatment of polycystic ovary syndrome, can solve the problems of large side effects, application restrictions, and restrictions on the selection of drugs for PCOS insulin resistance, and achieve obvious therapeutic effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0018] Effect of Example 1 Compound on 3T3-L1 Cellular Insulin Resistance Model
[0019] The following compound standard products were purchased from Beijing Laiyao Biotechnology Co., Ltd., and the specific structural formula is as follows:
[0020]
[0021]
[0022] The above-mentioned compounds are all isolated from the plant Epimedium, and the structure has been reported by the prior art, and those skilled in the art can also extract and separate Epimedium according to the relevant literature.
[0023] Model preparation: the cultured 3T3-L1 cells were mixed with 1×10 5 Individuals / ml were inoculated in 6-well plates, and cultured with low-sugar DMEM medium containing 10% FBS. After culturing for 48 hours, induction medium (10% FBS, 1.0umol / L dexamethasone, 0.5mmol / L IBMX , 10ug / L insulin, low-sugar DMEM medium), the medium was changed every 72 hours after induction, and the cells were digested and harvested after 6 days of induction. Wash 3 times with PBS at 1 x 10...
Embodiment 2
[0034] Example 2 Effect of pharmaceutical composition on 3T3-L1 cell insulin resistance model
[0035] On the basis of the above experiments, we continued to investigate the therapeutic effect of compound 1 in combination with a compound (berberine) known in the prior art to treat insulin resistance. The investigation method was the same as in Example 1, and the specific dosage regimen was as follows:
[0036] Administration group 1 was given compound 1 with a final concentration of 5umol / L; administration group 2 was given berberine with a final concentration of 5umol / L; administration group 3 was given compound 1 with a final concentration of 5umol / L and berberine with a final concentration of 5umol / L ; Administration group 4 was given metformin with a final concentration of 10umol / L; the control group and the model group were given the same amount of medium, and relevant measurements were carried out after 48 hours of culture.
[0037] The specific results are as follows:...
Embodiment 3
[0042] Effect of Example 3 compound and pharmaceutical composition on DHEA-induced polycystic ovary syndrome insulin resistance model ring
[0043] Modeling method: 21-day-old female wistar rats were taken, and after being adaptively fed for one week, they were randomly divided into groups of 10 rats. On the day of grouping, except the control group, other groups of rats were injected with 0.2ml (6mg / 100g) of DHEA was injected once a day for 20 consecutive days, and the control group was injected with the same amount of normal saline. After 20 days of injection, the model rats were fasted, and blood was collected 12 hours later to detect fasting blood glucose (glucose meter) and fasting insulin (insulin ELISA kit). According to the calculation method of insulin resistance index, HOMA-IR=fasting blood glucose (mmol / L)×fasting insulin (mU / L) / 22.5. Model rats with HOMA-IR>2.8 were used for subsequent experiments.
[0044] Dosing method: After successful modeling, each drug ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More